目的：观察甘露聚糖肽注射液联合吡柔比星预防浅表性膀胱癌术后复发的临床疗效。方法：选取本院2012年4月至2014年2月收治的浅表性膀胱癌患者60名，随机分为吡柔比星组和吡柔比星+甘露聚糖肽组，每组30例，观察药物治疗后对患者一年、两年及三年内癌症复发率、不良反应，采用ELISA法检测对尿液中IL-8的影响，利用案例分析法、比较分析法及统计学方法分析结果。结果：1）治疗一年、两年及三年内，吡柔比星+甘露聚肽糖联用组的复发率均低于吡柔比星组，均具有统计学意义（P＜0.05）。2）经第一、二次灌注后，联用组IL-8含量与吡柔比星组比较显著降低（P＜0.05），且低于治疗前（P＜0.01）；第三、四、五次灌注后联用组IL-8含量与吡柔比星组有极显著性差异（P＜0.01），且与治疗前比较更低（P＜0.01）。3）与吡柔比星组比较，联用组尿频/尿急、血尿发生率更低，具有统计学意义（P＜0.05）；连用组恶心呕吐、尿常规异常发生率低于吡柔比星组，有极显著性差异（P＜0.01）；而两组腹泻、低热比较无统计学意义（P＞0.05）。结论：甘露聚糖肽注射液联合吡柔比星膀胱灌注能显著降低浅表性膀胱癌患者术后的复发率、不良反应，并且可以降低患者尿液中IL-8含量。

Objective: To observe the curative effect of the recurrence of superficial bladder cancer treated with mannatide injection and pirarubicin.Methods: 60 patients with superficial bladder cancer were chosen in our hospital during April 2012 to February 2014 to be divided randomly into pirarubicin group and mannatide+pirarubicin group with 30 cases in each group, and there was an observation in cancer recurrence rate and untoward effect about drug treatment for patients after one year,two years and three years, ELISA method was used to detect the influence on IL-8 in the urine, results were analysed by using the case analysis method, comparative analysis and statistical analysis.Results:(1) Recurrence rate in combination group were lower than pirarubicin group with statistically significant (P 0.05).Conclusion: Mannatide Injection combined with pirarubicin can significantly reduce the recurrence rate, adverse reactions of patients with superficial bladder cancer, and decrease the

目的：探讨吡柔比星和卡介苗两种不同药物膀胱癌注射化疗，预防浅表性膀胱癌术后复发的疗效和安全性。方法对60例行尿道膀胱癌电切术后的浅表性膀胱癌患者，随机分为两组，每组30例，一组用吡柔比星，一组用卡介苗。分别于术后1-2周开始膀胱灌注，比较两组肿瘤复发率和并发症。结果随访6-36个月，两组的复发率分别为10%和13.3%，卡介苗并发症多于吡柔比星。结论吡柔比星膀胱灌注预防浅表性膀胱癌术后复发疗效满意，副作用轻，耐受性良好。

Objective to investigate two different drugs actos is soft than the star and the BCG vaccine injection bladder cancer chemotherapy, efficacy and safety of prevention of postoperative recurrence of superficial bladder cancer. Methods 60 routine urethral cutting postoperative patients with superifcial bladder cancer, bladder cancer were randomly divided into two groups, 30 cases in each group, a group with actos is soft than star, a set of BCG vaccine. In 1-2 weeks after operation respectively to bladder perfusion, compared two groups of tumor recurrence rate and complication. Results followed up for 6 to 36 months, two groups of recurrence rates were 10%and 13.3%respectively, the BCG vaccine complications than actos is soft than the star. Conclusion pyrazole soft than star bladder perfusion prevention of postoperative recurrence of superifcial bladder cancer curative effect satisfaction, side effect is light, well tolerated.

目的：评价南京地区27家样本医院2011~2013年抗肿瘤抗生素使用情况及特点，了解抗肿瘤抗生素治疗新理念和应用新药的新途径。方法：用限定日剂量法（DDDs）分析2011~2013年样本医院抗肿瘤抗生素应用的品种、数量、金额、日均用量数（DDDs）及日均费用（DDC）等情况。结果：抗肿瘤抗生素销售金额及销量逐年上升，最常用的是蒽环类抗肿瘤抗生素，已成为抗肿瘤抗生素的主体，销售金额排名前几位的药物主要是表柔比星、伊达比星、吡柔比星和阿霉素；DDDs排名前几位的药物主要是表柔比星、吡柔比星、丝裂霉素和阿霉素。大多数抗肿瘤抗生素的销量与使用同步性良好。结论：抗肿瘤抗生素的需求量逐年增加，尤其是蒽环类药物成为抗肿瘤抗生素的主流药物。

Objective: To comprehend the new therapeutic idea and way of using new drugs by estimating the using situation of anticancer antibiotics from 2011 to 2013 in 27 sample hospitals of Nanjing. Methods: With the method of defined daily dose (DDDs), the use of anticancer antibiotics was analyzed in respect of drug categories, consumption quantity, sales amount, DDDs and defined daily consumption (DDC), etc., from 2011 to 2013 in 27 sample hospitals. Results: The sales amount of anticancer antibiotics increased year by year, and the most commonly used drugs were antharcycline. The top four sales amounts were pharmorubicin, idarubicin, pirarubicin and adriamycin, the top four DDDs were pharmorubicin, pirarubicin, mitomycin and adriamycin. Most of the anticancer antibiotics sales amounts and the DDDs were concordant. Conclusion: The demand of anticancer antibiotics increased year by year. They have broad development prospects, especially antharcycline will become the leading anticanc

探讨经尿道膀胱肿瘤电切术(TURBT)术后行吡柔比星膀胱灌注不同保留时间对化疗效果的影响。方法:选TURBT术后患者70例,随机等分成观察组和对照组,两组均行吡柔比星膀胱灌注,观察组灌注保留时间为1 h,对照组灌注保留时间1.5 h,比较两组患者灌注后膀胱刺激症状、继发性出血、膀胱痉挛发生率。结果:观察组出现膀胱刺激症状、膀胱继发出血、膀胱痉挛发生率明显低于对照组(P0.05),具有统计学意义。结论:TURBT术后行吡柔比星膀胱灌注,在化疗效果相同的情况下膀胱灌注1 h较合适,较少出现并发症,患者较满意。

To discuss the effect of chemotherapy and satisfaction of pirarubicin intravesical with different retention time after transurethral bladder tumer resection ( TURBT) . Methods:70 cases of postoperative patients were randomly divided into observation group ( intravesical time was 1 h) and control group (the intravesical time was 1. 5 h). To compare the incidence of bladder irritation,secondary hemorrhage and blodder spasms after intravesical of two groups. Results:The incidence of complications in observation group was lower than the control group (P<0. 05). Conclusion:Intravesical with prarubicin after TURBT,treatment effect was mutually,use prarubicin to irrigation of bladder,1 h was better.

目的：探讨膀胱灌注吡柔比星预防浅表性膀胱癌术后复发的疗效及安全性。方法：对116例浅表性膀胱癌患者行经尿道膀胱肿瘤电切术或膀胱部分切除术。术后1周开始用吡柔比星进行膀胱内定期灌注，每次药物在膀胱内保留30～60min。每周1次，连续8次，以后每月次，连续10次。并随访。结果：116例患者均未见全身性药物不良反应。仅9例患者出现轻微膀胱刺激症状。复发19例，复发率16．37％。结论：膀胱内灌注吡柔比星预防膀胱癌术后复发的疗效确切，不良反应少，安全性好，在灌药时加强对患者灌注前、灌注中及灌注后护理，可减轻患者不适感，提高患者灌药的依从性。

Objective To investigate the nursing of which bladderwas perfused Pirarubicin(THP)toprevent postoperative recurrence of su-perficial bladder cancer .Methods 116 cases of patients with superficialbladder cancer through transurethral resection of bladder tumor (TURbt)orpartial cystectomy .After postoperative one week ,30mgPirarubicin was dissolved into 40 ml of 5% glucose infusion bladder regu-larly ,combinationwith the necessary care before and after perfusion .Results 116 cases were not seen systemic adverse drugreactions .only nine cases of mild bladder stimulation symptoms in patients .19case recurrence of bladder cancer(16 .37% ) .Conclusion To the prevention of post-operative recurrenceof bladder cancer ,the bladder with THPperfusion combination with the care during the perfusion were the exactefficacy , safety ,w hichreduced discomfort of the patient ,andimproved the patients of compliance reperfusion .